 NEW YORK, Feb. 25, 2021 GLOBE NEWSWIRE -- Bragar Eagel Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Pandion Therapeutics, Inc. NASDAQ: PAND breached their fiduciary duties or violated the federal securities laws in connection with the companys acquisition by Merck Co., Inc. NYSE: MRK. 